99 related articles for article (PubMed ID: 7753547)
21. A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation.
Gu J; Rubin RM; Yuan ZM
Oncogene; 2001 Jun; 20(27):3519-27. PubMed ID: 11429698
[TBL] [Abstract][Full Text] [Related]
22. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
23. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation.
Medcalf EA; Milner J
Oncogene; 1993 Oct; 8(10):2847-51. PubMed ID: 7690928
[TBL] [Abstract][Full Text] [Related]
24. HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence.
Thomas M; Massimi P; Banks L
Oncogene; 1996 Aug; 13(3):471-80. PubMed ID: 8760288
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
[TBL] [Abstract][Full Text] [Related]
26. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
[TBL] [Abstract][Full Text] [Related]
27. A genetic approach to mapping the p53 binding site in the MDM2 protein.
Freedman DA; Epstein CB; Roth JC; Levine AJ
Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
[TBL] [Abstract][Full Text] [Related]
28. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
Freedman DA; Levine AJ
Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
[TBL] [Abstract][Full Text] [Related]
29. p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16.
Akutsu N; Shirasawa H; Asano T; Isono K; Simizu B
J Gen Virol; 1996 Mar; 77 ( Pt 3)():459-63. PubMed ID: 8601782
[TBL] [Abstract][Full Text] [Related]
30. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.
Galatin PS; Abraham DJ
J Med Chem; 2004 Aug; 47(17):4163-5. PubMed ID: 15293988
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of p53 DNA binding by human papillomavirus E6 proteins.
Lechner MS; Laimins LA
J Virol; 1994 Jul; 68(7):4262-73. PubMed ID: 8207801
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
33. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
34. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
[TBL] [Abstract][Full Text] [Related]
35. DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner.
Qi M; Zhang J; Zeng W; Chen X
Biochim Biophys Acta; 2014 Jan; 1839(1):62-9. PubMed ID: 24361594
[TBL] [Abstract][Full Text] [Related]
36. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
[TBL] [Abstract][Full Text] [Related]
37. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.
Sharp DA; Kratowicz SA; Sank MJ; George DL
J Biol Chem; 1999 Dec; 274(53):38189-96. PubMed ID: 10608892
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
[TBL] [Abstract][Full Text] [Related]
39. Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins.
Domenici F; Frasconi M; Mazzei F; D'Orazi G; Bizzarri AR; Cannistraro S
J Mol Recognit; 2011; 24(4):707-14. PubMed ID: 21584881
[TBL] [Abstract][Full Text] [Related]
40. Tumor promotion by Mdm2 splice variants unable to bind p53.
Fridman JS; Hernando E; Hemann MT; de Stanchina E; Cordon-Cardo C; Lowe SW
Cancer Res; 2003 Sep; 63(18):5703-6. PubMed ID: 14522887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
